Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 versus intravesical chemotherapy in FGFR-altered high-risk non-muscle-invasive bladder cancer after BCG
NL-OMON60330Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Started Jan 2026; status: recruiting.
02
Drugs
erdafitinib
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60330.